PA
INGN icon

PharVision Advisers’s Inogen INGN Stock Holding History

PharVision Advisers’s Portfolio INGN Stock Details INGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.9K Buy
+13,473
New +$89.2K 1.64% 27
2026
Q1 		– Sell
-55,240
Closed -$371K – 366
2025
Q4 		$371K Buy
+55,240
New +$414K 0.19% 149
2025
Q1 		– Sell
-18,885
Closed -$173K – 390
2024
Q4 		$173K Buy
+18,885
New +$177K 0.15% 333

Other funds holding INGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's INGN Position: Q2 2026 in Review

PharVision Advisers opened a new position in Inogen (INGN) in Q2 2026: 13,473 shares worth $86.9K. The stake represents 1.64% of the portfolio and ranks #27 among its holdings. This is a return to the name: PharVision Advisers previously reported a position in INGN as recently as Q4 2025.

PharVision Advisers first reported a position in INGN in Q4 2024 and has held it in 3 quarters since. The position peaked at $371K in Q4 2025. 129 funds tracked by Wall St. Rank hold INGN as of Q2 2026.

  • PharVision Advisers held 13,473 shares of Inogen worth $86.9K as of Q2 2026.
  • Inogen was a new PharVision Advisers position in Q2 2026.
  • Inogen made up 1.64% of PharVision Advisers's portfolio in Q2 2026, its #27 holding.
  • PharVision Advisers first reported a position in Inogen in Q4 2024 and has held it in 3 quarters since.
  • PharVision Advisers's Inogen position peaked at $371K in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Inogen as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.